Inhibiting the extracellular signal-regulated kinase 1/2 (erk1/2) cascade in cancer and the heart: for better or worse, in sickness and health?

HIGHLIGHTS

• What: The authors focus on the drugs which target the pivotal signalling cascade that drives cell division, the prototypic mitogen-activated protein_kinases (MAPKs) now known as the extracellular signalregulated kinases 1/2 (ERK1/2) . None of the studies show QT prolongation with dabrafenib and hypertherapeutic dosing with dabrafenib has no effect on QT interval , so the effect of vemurafenib (and possibly encorafenib) does not appear to be related to inhibition of BRAF per se.
• Who: Angela Clerk * and colleagues from the School of Biological Sciences, University of Reading, Reading , AS, UK have published the Article . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.